Tolerance and effectiveness of anti–tumor necrosis factor α therapies in elderly patients with rheumatoid arthritis: A population‐based cohort study
Stéphane Genevay(University of Geneva), Cem Gabay(Hôpital Beau-Séjour), Axel Finckh(University Hospital of Geneva), Diego Kyburz(University of Basel), Adrian Ciurea(University of Zurich), Anne‐Marie Chamot(Hôpital de Morges)
Cited by 125
Related Papers
What low back pain is and why we need to pay attention
|The Lancet|2018|4.7k
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update
|Annals of the Rheumatic Diseases|2020|2.8k
Prevention and treatment of low back pain: evidence, challenges, and promising directions
|The Lancet|2018|2.5k
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update
|Annals of the Rheumatic Diseases|2022|1.9k
2022 update
|Radboud Repository (Radboud University)|2010|1.6k